论文部分内容阅读
本文回顾了174例应用同一化疗方案的成年急性粒细胞白血病(AML)病人,分析某些细胞学参数的预后价值。结果:174例AML病人均接受“AML5”方案化疗(阿霉素50mg/M~2第一天;长春新硷1mg/M~2第二天和阿糖胞苷80mg/M~2每12小时静注第3-9天),且均经FAB分类。M_1和M_5的骨髓原始细胞百分比显著高于M_2和M_4,原始细胞低于80%的病例分别为:M_1占4.5%;M_271.8%;M_440%和M_513%。Auer’s体阳性细胞占骨髓原始细胞总数的百分率与年龄、骨髓
This article reviews 174 adult acute myelogenous leukemia (AML) patients who were treated with the same chemotherapy regimen and analyzed the prognostic value of certain cytological parameters. RESULTS: All 174 AML patients received “AML5” regimen chemotherapy (50 mg/M~2 for the first day of doxorubicin; 1 day for Changchun Xinxie, and 12 days for cytarabine 80 mg/M~2). Intravenous injections (3-9 days) were all classified by FAB. The percentage of bone marrow blast cells in M_1 and M_5 was significantly higher than that in M_2 and M_4, and the cases with less than 80% of blast cells were: M_1 accounted for 4.5%; M_271.8%; M_440% and M_513%. The percentage of Auer’s positive cells in the total number of bone marrow blasts and age, bone marrow